Orange Book product · Brand (NDA)
ADCIRCA
TADALAFIL
At a glance
May 22, 2009
Approved
Brand (NDA)
Application
AB2
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 22, 2009
17 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
TADALAFIL
Strength
20MG
Dosage form
TABLET
Route
ORAL
TE code
AB2
Application
NDA 022332
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2024CHEWTADZYBrand (NDA)
NDA 218527 · B BETTER
- 2022TADLIQBrand (NDA)
NDA 214522 · CMP DEV LLC
- 2008CIALISBrand (NDA)
NDA 021368 · LILLY
- 2026TADALAFILGeneric (ANDA)
ANDA 210329 · JUBILANT GENERICS
- 2024TADALAFILGeneric (ANDA)
ANDA 216279 · SHANDONG
- 2024TADALAFILGeneric (ANDA)
ANDA 217606 · FOURRTS LABS
- 2023TADALAFILGeneric (ANDA)
ANDA 212515 · ZYDUS PHARMS
- 2023TADALAFILGeneric (ANDA)
ANDA 215949 · NOVITIUM PHARMA
- 2022ALYQGeneric (ANDA)
ANDA 216932 · TEVA PHARMS INC
- 2022TADALAFILGeneric (ANDA)
ANDA 210609 · PRINSTON INC
- 2022TADALAFILGeneric (ANDA)
ANDA 210608 · PRINSTON INC
- 2021TADALAFILGeneric (ANDA)
ANDA 215556 · VKT PHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
